Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting

Clicks: 81
ID: 118682
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #81 of 85 articles by views in Annals of hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In most patients, mantle cell lymphoma (MCL) shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3–5 years. In the current study generation of the European MCL Network, the addition of high-dose Ara-C to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen followed by myeloablative consolidation achieved a significant improvement of progression-free survival in younger patients. In elderly patients, rituximab maintenance led to a marked prolongation of remission duration. Emerging strategies include mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, immune modulatory drugs, Bruton’s tyrosine kinase inhibitors and others, all based on the dysregulated control of cell cycle machinery and impairment of several apoptotic pathways. Combination strategies are currently being investigated in numerous trials, but their introduction into clinical practice and current treatment algorithms remains a challenge. In the current survey, the application of the molecular targeted compounds were collected and evaluated by a representative national network of 14 haematological institutions. Optimised strategies are recommended for clinical routine. Future studies will apply individualised approaches according to the molecular risk profile of the patient.
Reference Key
witzens-harig2012annalscurrent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M. Witzens-Harig;G. Hess;J. Atta;M. Zaiss;G. Lenz;C. Scholz;R. Repp;M. Reiser;C. Pott;H. Pelz;P. La Rosée;H. Kirchner;P. Kiewe;U. Keller;C. Buske;A. Viardot;M. Dreyling;M. Witzens-Harig;G. Hess;J. Atta;M. Zaiss;G. Lenz;C. Scholz;R. Repp;M. Reiser;C. Pott;H. Pelz;P. La Rosée;H. Kirchner;P. Kiewe;U. Keller;C. Buske;A. Viardot;M. Dreyling;
Journal Annals of hematology
Year 2012
DOI
doi:10.1007/s00277-012-1534-y
URL
https://link.springer.com/article/10.1007/s00277-012-1534-y
Keywords
oncology hematology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.